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ABSTRACT
DESIGN AND SYNTHESIS OF NON-XANTHONE STRUCTURAL ANALOGS
OF α-MANGOSTIN
Maryam Foroozmehr
α-Mangostin belongs to a class of polyphenolic compounds called xanthones. The
potential pharmacological effects such as anti-bacterial and anti-cancer effects of αmangostin have made it an important natural product for medicinal chemistry evaluation.
During this thesis research, we have designed and synthesized a series of non-xanthone
analogs of α-mangostin for medicinal chemistry evaluation. A commercially available
starting material, methyl-4-methoxysalicylate was used to synthesize these non-xanthone
analogs. The analogs were designed as more flexible derivatives compared to the tricyclic
motif within α-mangostin yet retain the hydroxybenzoate scaffold. Through a one-pot
chemical synthesis, with relatively high yield (70%), we prepared eight different benzylether analogs. The benzyl-ether scaffolds contained various substituents at the 4-positon
of the aryl ring, and we evaluated the effect of these substituents on the antibacterial
activity. Moreover, the alkylation chemistry we have utilized is very simple to do and
suitable for the large-scale preparation of these analogs. The chemical approach reported
here can be extended to incorporate various benzyl and alkyl motifs at the 2-position of
the methyl-4-methoxysalicylate core for elaborate medicinal chemistry efforts. Our initial
antibacterial activity evaluation of selected derivatives from this series showed no
activity at 100 µM concentration against S. aureus and S. epidermidis strains. Our future
plan is to evaluate the antibacterial activity of these analogs against a larger panel of
bacteria.
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CHAPTER 1. INTRODUCTION
1.1 Chemistry of xanthones:
Xanthones are an important class of oxygenated heterocycles and are known to exhibit a
broad range of biological activities1. Many naturally occurring xanthones have been
identified and characterized to date1. Their structural diversity and pharmacological
importance have made xanthones an important class of molecules for drug discovery. As
a result, a number of different synthetic xanthone derivatives have been reported in the
literature2. The xanthone scaffold is made up of a γ-pyran moiety in the middle, fused
with two benzene rings3. There are different numbering methods for the basic xanthone
carbon skeleton in the literature, but the IUPAC provisional recommendations of 2004
for this tricyclic ring is based on a biosynthetic convention in which carbons 1-4 are
devoted to ring B (acetate-derived ring) and the carbons 5-8 are assigned to ring A
(shikimate-derived), (Figure 1)4.

Figure 1. Structure of a xanthone core and IUPAC numbering of the scaffold.
1.2 Classification of xanthones:
Naturally occurring xanthones are classified into six different groups based on their
substituents2. The most abundant naturally occurring xanthones are prenylated (60%)
followed by simple (25%) and glycosylated (11%) xanthones.
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1. Simple oxygenated xanthone
2. Xanthone glycosides
3. Prenylated xanthone
4. Bisxanthones
5. Xantholignoids
6. Miscellaneous xanthones
1.2.1 Simple oxygenated xanthone:
The substituents simply include hydroxyl, methoxy or methyl groups which depending on
the level of the oxygenation could be subdivided in other groups like mono, di, tri, tetra,
penta or hexa oxygenated. As per figure 2, 2-hydroxyxanthone and 2-hydroxy- 1methoxyxanthone are two examples.
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O
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O

HO
O

O
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1

Figure 2. Structures of oxygenated xanthones.
The reported biological activities exclusively related to this group of xanthones include a
wide variety of effects. Two of the compounds with their known pharmacological effects
are trihydroxy xanthone with antibacterial activity 5 and polyhydroxy6 and methyl7
substituent xanthones with antimycobacterial activity, also other pharmacological
activities attributed to this group are antimalarial8, antifungal5, CNS-depressant9, anticonvulsant/antiepileptics10, analgesics11, antihypertensive12, anticoagulant13, antiasthmatic14, hepatoprotective15, antidiabetics16, anti-inflammatory17, antiallergics14 and
antianaphylactics18.
2

This group of xanthones target a wide variety of enzymes, having very different effects
on them, including inhibitory effect on: acetylcholinesterase19, cyclooxygenases (COXs)
through COX-2 gene expression inhibition20, cyclic AMP-phosphodiesterase 21, cyclic
GMP-phosphodiesterase18, lipoxygenase20, nitric oxide synthase22, aspartic23,
topoisomerases I and II24, competitive reversible selective inhibition of monoamine
oxidase A and B25, competitive inhibition of MMLV26 and non-competitive inhibition of
hypoxantine-xanthine oxidase27.
Oxygenated xanthones extracted from Swertia chirata showed them decreasing the
activity of Catalase28, superoxide dismutase29 and glutamic acid decarboxylase9.
Also, this group of xanthones isolated from Swertia chirata enhanced the activity of
glutathione-S-transferase and glutathione peroxidase28.
Tetra-oxygenated derivatives isolated from Tripterospermum lanceolatum showed them
inhibitory activity toward Angiotensin-I-Converting Enzyme30, phospholipase C 27and
increasing effect on the release of lactate dehydrogenase31. Another effect attributed to
this group is the activation of protein kinase C32.
Oxygenated xanthones modulate some other cellular systems as well. For instance,
tetraoxygenated xanthones can block the calcium channels33 and other types of
oxygenated xanthones showed complexation with heme in hemoglobin34, inhibition of
proliferation of lymphocytes35 and inhibition of human complement system36.
Moreover, oxygenated xanthones are among the naturally occurring xanthones with antitumor activity35. They do it through six various pathways: DNA binding, DNA synthesis
suppression, modulation of protein kinase C, post-replication repair interference,
3

topoisomerases I and II inhibition. Also, tetraoxygenated xanthones inhibit phospholipase
C37.
1.2.2 Xanthone glycosides:
Xanthone glycosides have a sugar moiety attached to the main tricyclic structure. There
are two types of xanthone glycosides: C-glycoside, where the sugar is attached to the
main structure by C-C bond, and O-glycoside where its linkage is through C-O-C bond.
Most of the xanthone glycosides are O-glycoside type. Examples include mangiferin (3)
and isomangiferin as the most common C-glycosides, and gentioside (4) as O-glycosides.
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Figure 3. Structures of two representative xanthone glycosides.
The biological activities attributed to this group includes: antiparasitic38, antiviral39,
antiretroviral40, CNS-depressant41, CNS-stimulant42, analgesics43, antilipemic44,
antiplatelet-anticoagulants45, hepatoprotective46, antidiabetics47, anti-inflammatory48,
antiallergics38 and immunomodulator49.
The enzyme system modulatory effects the xanthone glycosides contain are inhibitory
activity toward: Aldose reductase50, cyclooxygenase51, α-glucosidase37, creatine kinase47a
and competitive inhibition toward isomaltase and sucrase52, reductase53 plus competitive
reversible selective inhibition toward monoamine oxidase A and B54, inhibition of gene
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expression toward nitric oxide synthase55, also has decreased the activity of superoxide
dismutase47a.
Xanthones with glycosyl substitution have been shown to affect two different cellular
systems. First, activation of proliferation of lymphocytes56 and second, inhibition of
phagocytic activity of macrophages, controlling the expression of genes for primary
inflammation mediators48, 55.
Glycosylated xanthones are among the xanthones with anti-cancer activity57. They go
through different pathways such as transforming growth factor-β (TGF-β) gene
expression, increasing and apoptosis induction via active caspase 3 pathways.
1.2.3 Prenylated xanthone:
In this group of xanthones a 5-carbon unit is attached as substituent to the xanthone core.
Allanxanthone-A with two isoprenyl groups in positions 2 and 4 is shown below as an
example of this kind (Figure 4).

O

OH
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O

4

OH

OH
5

Figure 4. Structure of prenylated xanthone.
Different biological activities of members in this group have been proven, including:
antibacterial58, antimalarial59, antifungal23, antiretroviral60, CNS- depressant61,
neurological disorders62, antiplatelet-anticoagulant63 and anti-inflammatory61 effects.
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Prenylated xanthones have different effects on a vast number of enzymes. Some good
examples are inhibition of acetylcholinesterase37, cyclooxygenases64, cyclic-AMPphosphodiesterases65, calcium dependent protein kinase66, myosin light chain kinase66,
Aspartic23, HIV-1 protease67, sphingomyelinases68, topoisomerases I and II37 and noncompetitive inhibition of: calcium ATP-ase57, cyclic-AMP-binding phosphatase66, and
competitive inhibition of: protein kinase C66, cyclic AMP dependent protein kinase66.
This type of xanthone other than inhibitory effect against above-mentioned enzymes can
activate caspase-369 and caspase-970 enzymes.
Prenylated xanthones have modulatory effects on P-glycoprotein71 and block the
prostaglandins D2, E1, E264, and act as antagonist toward three different receptors: 5HT
2A72, histamine H173 and platelet activity factor63.
Prenylated xanthones have anti-cancer activities74 and do it through seven different
pathways: apoptosis induction via active caspase 3 pathways, modulation of protein
kinase C and A and mitogen-activated protein kinase, prostaglandin E2 receptors
blocking, sphingomyelinases inhibition and topoisomerases I and II inhibition37.
1.2.4 Bisxanthones:
This group of xanthones have dimeric structures. The first of this kind was extracted from
a plant, and a total of 12 different kinds of bisxanthones have been isolated.
Globulixanthone E (6) and Ploiarixanthone (7) are two examples of this kind (Figure 5).
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Figure 5. Structures of select bis-xanthones.
The known biological effects of this group of xanthones are antimycobacterial,
antimalarial75, antihypertensive and antiplatelet-anticoagulant activity76.
The dimers affect different enzymes in different ways including: decreasing the activity
of catalase and superoxide dismutase28 and enhancing the activity of glutathione
peroxidase and glutathione-S-transferase28.
1.2.5 Xantholignoids:
This group makes one of the important types of xanthones and are thought to be
biosynthesized by coupling of cinnamoyl alcohol with an O-hydroxyxanthone. Below
you can find some examples of this group of xanthones which are named as Kielcorin, 6methylkielcorin, Hypericorin, and Cadensin C (Figure 6).
R1

R2

O
O
O

O
O

(a) R1 = R2 = R3 = R4 = H, R5 = Me, Kielcorin
HO
(b) R1 = R3 = R4 = H, R2 = R5 = Me, 6-Methylkielcorin
(c) R1 = OH, R2 = R4 = H, R3 = OMe, R5 = Me, Hypericorin
(d) R1 = R2 = R4 = H, R3 = OMe, R5 = Me, Cadensin C
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Figure 6. Structures of select xantholignoids.
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The reported biological activity related to xantholignoids is just hepatoprotectivity15.
Also there are two enzymes affected by this group of xanthones in the literature including
protein kinase C77 and topoisomerases I and II24 which are inhibited by this group and
results in its anti-cancer activity37.
This group of xanthones have shown inhibition of proliferation of lymphocytes78.
1.2.6 Miscellaneous xanthones:
Other types of xanthones with any substituent other than the above-mentioned substituent
is included in this group. There are different examples including: xanthopterin,
xantholiptin, and xanthofulvin (9) and vinaxanthone (10) (Figure 7).
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Figure 7. Structures of two different natural xanthones, containing a flavone moiety.
Almost all the above-mentioned biological activities for other groups can be included
here for different substituents in miscellaneous group. Some of the most common
activities are antiosteoprotics effects for propoxy/ipriflavone analogs79, antiretroviral
effects for flavone-xanthones67, antiviral80 and antifungal81 effects for furano-xanthones.
Xanthone flavones have shown inhibitory activity toward DNA- polymerases82 and
human DNA ligase I83 and competitive inhibition toward HIV-184. Also furano-xanthones
8

have shown inhibition of topoisomerases I and II37. Xanthone- anthraquinone has shown
inhibitory activity toward steroid 11-β-hydroxylase85 which lead to their anti-cancer
activity. On the other hand, xanthones substituted with chloro, bromo and alkyl have
shown competitive reversible selective inhibition toward monoamine oxidase A and B86.
Different xanthones in this group have different effects on cellular systems such as
xanthones with carboxy and tetrazole substituents which are binding to albumin87 or
xanthones with nitro substituents which make complexation with heme in hemoglobin88.
Xanthones in this group with epoxy substituent have shown good anti-cancer activity.
They go through different pathways such as DNA synthesis suppression, protein
synthesis suppression, RNA synthesis suppression and signal transduction inhibition in
Ha-ras oncogene37.
From a chemical point of view, there are rules for the molecular structure of a compound
such as: less than 500 Da of molecular weight, less than 5 and 10 hydrogen bond donors
and hydrogen bond acceptors respectively and a less than 5 partition coefficient (log P)89
, which make a compound as a promising drug-candidate. Most xanthones follow all
these criteria and frameworks, but exactly how each of these structures produce each
specific above-mentioned pharmacological effect is a complex discussion above this
study. However, in the following sections (1.4-1.6), the relationship between the
chemical structure and two specific attributed pharmacological effects of a particular type
of xanthone (α-mangostin) that has been considered in this study will be discussed in
detail.

9

1.2.7 Isolation of xanthones:
The distribution of each class of xanthones in different plants genera is shown in figure
81. As expected, simple xanthones can be found in all important families since they are
considered to be the precursor of all other classes of xanthones. The Clusiaceae family
(mainly represented by Garcinia) is the most important source of prenylated xanthones
while xanthone glycosides are mostly found in Gentianaceae family (represented by
Swertia and Gentianella genera).

Figure 8. Heatmap for the distribution of different xanthone classes by genera (20122019).
[Figure adapted from: Klein-Júnior, L. C.; Campos, A.; Niero, R.; Corrêa, R.; Vander
Heyden, Y.; Filho, V. C., Xanthones and Cancer: from Natural Sources to Mechanisms of
Action. Chemistry & biodiversity 2020, 17 (2), e1900499.]

Among all the pharmacological properties of xanthones, in this study the anti-bacterial
and anti-cancer properties of the synthesized analogs are planned to be surveyed.
Consequently, herein we would clarify the relationship between the structure and the
biological activity of natural and previously made xanthone compounds specifically in
these two medical conditions.
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1.3 Natural xanthones from mangosteen fruit:
Mangosteen (Garcinia mangostana) is an evergreen, slow growing tropical tree from the
Clusiaceae family, indigenous to southeast Asia but can be found in various tropical
regions around the world too. Most of its long-lasting fame is due to its exotic fruit and
the variety of medicinal properties it has. The deep purple colored pericarp of
mangosteen fruit is the abundant source of a class of polyphenolic compounds called
xanthones, largely responsible for its biological activities and health promoting
properties90. The pharmacological properties of xanthones and their derivatives consist of
a diverse range including anti-cancer, anti-oxidant, anti-bacterial, anti-fungal, antiinflammatory, anti-malarial, anti-HIV and anti-convulsant activities plus inhibitory effect
on a wide range of enzymes including acetylcholinesterase (AChE) and
butyrylcholinesterase (BChE) which have therapeutic potential in the field of
Alzheimer’s disease91, α-glucosidase with the potential of treatment of many diseases
including diabetes mellitus type II92, in addition to inhibitory effect on some other
enzymes like topoisomerase, protein kinase and aromatase3. Moreover, some benefits of
xanthones in cardiovascular diseases have been shown4. Between 2012 and 2019 a total
number of 1225 xanthones was isolated from different plants, and 48% of those were
found in Clusiaceae family93. More specifically more than 60 of them have been
identified exclusively in mangosteen94. To isolate these compounds classical methods
like column chromatography has been used and the structure determination has been
achieved using MS and NMR methods93. The most abundant type of xanthone has been
identified in mangosteen fruit is α-mangostin (Figure 9) , which is one the most studied
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xanthones with many proved pharmacological efficacies considerably the most cancerpreventive potency among other xanthones90.
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Figure 9. Structure of α-mangostin.
Isolation of α-mangostin from natural resources is not trivial due to solubility problems
and low yield95. Hence, there is a limited structure-activity relationship knowledge
available in the literature. One of the ways to better understand the biological profiles of
α-mangostin is through chemical synthesis of analogs, with simpler structure.
1.4 Anti-cancer activity of α-mangostin:
Today, cancer is the leading cause of death among the societies and more importantly, its
main cause is the poor treatment. There are three different cancer treatment approaches:
surgery, radiotherapy, and chemotherapy. The anti-cancer drugs have low selectivity and
high toxicity which recommend the necessity of production of new chemotherapeutic
agents with high selectivity and low toxicity95. However, one of the promising ways, is
dietary chemoprevention by using naturally occurring phytochemicals like xanthones
with proved anti-cancer activity and apparent safety90. These secondary metabolites have
shown selectivity for cancer cells with minimal damage to normal cells and that is why
they have attracted medicinal chemists’ attention as candidates for a new and safe anticancer drug93.
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α-Mangostin, which is the most potent xanthone against prostate, breast, lung, and
colorectal cancer90 has shown inhibitory activity through various mechanisms of action96.
The in-vivo and in-vitro studies have revealed that it acts against cancer cells through
inhibition of proliferation, inducing apoptosis and cell cycle arrest, modulating phase I
and phase II enzymes, especially downregulation cyclins/cyclin dependent kinases
(CDKs) and also has blocking effect on the invasion and metastasis of various cancers
which demonstrates its potential as suppressing agent in relation to promotion and
progression of cancer i.e. reducing the growth of tumor93, 97.
Several studies have been reported to describe the medicinal chemistry and different
derivatives of α-mangostin for cancer treatment98. Due to the low water solubility of αmangostin, inserting some polar groups to its basic structure can increase its
hydrophilicity and anti-cancer properties. Based on the Fei et al. efforts a series of αmangostin analogs have been synthesized and examined on five human cancer cell lines
which several of those showed promising cytotoxicity activities against all the cell lines
in µM quantities. Among those the most potent analog with several times more
hydrophilicity compared to α-mangostin was the one with chloro group at C4 and phenol
groups at C3 and C6 (Figure 10). The structure activity relationship of this compound and
the other synthesized compounds showed that the presence of phenol groups on C3 and
C6 are critical for inhibition of cancer cells and the C4 modification can increase the
activity and drug-like properties. To synthesize analogs in this study α-mangostin has
been used as starting material99.

13

Figure 10. Substituted α-mangostin.
Some other studies suggested that the hydroxyl groups on isoprenyl side chains can
decrease the anti-cancer activity of α-mangostin, while the xanthones containing
tetraoxygen groups in their structure in addition to the isoprenyl side chains on ring A
and B have the most anti-cancer activity90, 100.
Yuanita et al. conducted a QSAR study on xanthones to find their active sites and design
molecules with highly predicted anti-cancer activity. Based on this research, the most
influential positions for anti-cancer activity are C1, C5, C6, C10 and C11 (Figure 11).
QSAR equations suggest that the more negative the atomic net charge of C5 and C6, and
the more positive the atomic net charge of C1, C10 and C11, the lower log IC50 (The half
maximal inhibitory concentration) and the higher anti-cancer potency. So to achieve this,
C5 and C6 or their neighbors are better to be occupied with electron donating groups like
hydroxyl or methoxy to make them more nucleophile groups and other positions
including C1, C10 and C11 are better to be occupied with electron withdrawing groups
like halogens and nitro group to remove the electron density from the П-system95.
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Figure 11. Influential positions for anti-cancer activity.
It also has been proven in some other literatures, that xanthones with bromo and chloro
substituents were the most potent inhibitors of topoisomerase II, having lower IC50
compared to doxorubicin, a commercially available anti-cancer drug101.
Among all the xanthone derivatives, one of the analogs with much attention as anticancer with remarkable effect is 5,6-dimethylxanthone‐4‐acetic acid (DMXAA) (Figure
12) which is from the carboxyxanthone family and is now in the phase III of clinical
trial102.
The regular synthesis method for DMXAA involves six steps starting with 2,3
dimethylaniline which undergo a heterogeneous reaction to form an isonitrosoacetanilide
with an overall 11% yield103.
Some efforts have been made during these years to find easier ways for this synthesis
with higher yield. Yang et al. found a four step method with >50% yield104.

Figure 12. Structure of DMXAA.
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1.5 Anti-bacterial activity of α-mangostin:
Antibiotic-resistance is one of the most threatening dangers for human health. There are
some reports about the resistance of some Gram-positive bacteria like methicillinresistant Staphylococcus aureus (MRSA) to different anti-biotics such as β-lactams
(oxacillin and ampicillin), vancomycin, fluoroquinolones, linezolid and daptomycin
which previously had been treated with these antibiotics. The result is more morbidity
and increased cost for healthcare. As a result, there is an urgent need for some new drugs
to fight against multi-drug resistant pathogens105.
α-Mangostin has demonstrated promising anti-bacterial effects. It has been proposed to
target the cytoplasmic membrane of Gram-positive bacteria such as MRSA. Also, it has
shown some promising advantages like low minimum inhibitory concentration, fast
bactericidal effect, and like some other naturally occurring antimicrobial peptides, lower
risk of development of resistance106. Nevertheless, due to the hydrophobicity it is not
selective toward prokaryotic cells. In other words, it cannot differentiate the mammalian
cells from bacteria, and it exhibits adverse toxicity. So, there is an interest in developing
new α-mangostin analogs with membrane selectivity105.
Zou et al. worked on some analogs by incorporating cationic substituents with different
pK a on the xanthone scaffold, to make these molecules more amphiphilic and such
strategy improved selectivity for bacterial membrane over mammalian cell. The
electrostatic interactions cause the attraction between the incorporated cationic groups
and the anionic phospholipid head groups in bacterial membrane. Compound AM-0016
(Figure 13) has shown the most potency as bactericidal over a range of Gram-positive
bacteria including MRSA with improved selectivity and no antibiotic resistance105.
16

Figure 13. Structure of compound AM-0016.
Due to the disappointing toxicity of the compounds made by Zou et al., more efforts have
been focused on the synthesis of new compounds with same potency but reduced
toxicity3. Among those the most successful examples include two compounds made by
Koh et al in 2015. By using the hydrophobic core of α-mangostin and substituting
lipophilic chains at C2 and C8, cationic amino acids at C3, produced potent antimicrobials effective against MRSA and VRE, with high selectivity, rapid kill, no
antibiotic resistance, and low toxicity. They also distinguished three important structural
components. First the need of a bis- or tri-cyclic rigid hydrophobic core. The small size
of the molecule and the conformationally constrained structure may enhance the
penetration into the Gram-positive membranes. Second, the cationic moieties which
afford the electrostatic interactions with bacterial membrane and provide the selectivity
over mammalian cells. Third, a lipophilic chain such as isoprenyl group or its reduced
form provide the sufficient driving force to penetrate the cytoplasmic membrane of
bacteria107.
Later, the same research group tried to make some more potent analogs with higher
selectivity and less hemolytic activity. They designed and synthesized 46 different new
compounds inspired by the nonpeptidic xanthone structures, and then divided them into
four groups based on spacer length, cationic moieties, lipophilic chains, and tri-arm
17

functionalization to evaluate their anti-microbial properties. Among those one of them
(Figure 14) with two primary amine groups showed the highest potency, acceptable
selectivity and less hemolytic activity108.

Figure 14. Structure of primary amine-conjugated.
Different strategies have been followed in this study to synthesize the compounds. But
the starting material in all of them was α-mangostin or using condensation of 2,4dihydroxylbenzoic acid and phloroglucinol in the presence of Eaton’s reagent. The yields
vary between 34% to 95%.
1.6 Chalcones: Structural mimics of xanthones:
In 2016 Cai et al. supported by their previous successful studies on the anti-diabetic and
α-glucosidase inhibitory effects of xanthones stated that, the key factors responsible for
the inhibitory effects of xanthones are H-bond, extended П-system, and the flexibility of
its structure. Further, they hypothesized that chalcones (Figure 15) as analogs of
xanthones can possess better inhibitory effects due to the flexibility of their structural
framework. It was proven by making twenty-six chalcones and bis-chalcones which those
with hydroxyl substituents showed better inhibitory activity against α-glucosidase
enzyme. The structure activity relationship suggests that the number and the place of the
hydroxyl groups affect inhibitory activity by acting as hydrogen bonding donor in
relation to the enzyme109.
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Figure 15. Structure of chalcones and bis-chalcones.
Chalcones also known as α,β-unsaturated ketones are an important naturally occurring
compounds belong to the flavonoid family. They exhibit many different pharmacological
and beneficial effects including anti-cancer and anti-bacterial effects109-110. As it is shown
in figure 15, their structure consists of two aromatic rings connected to each other by
three-carbon α,β-unsaturated carbonyl bridge. They can be synthesized both naturally in
plants and synthetically in the laboratory and are a preferred starting material to
synthesize other polycyclic aromatic compounds. That is why methods to synthesize
them is among popular research objectives. The most common method used to synthesize
them in the lab is aldol condensation of substituted acetophenones with proper substituted
benzaldehydes in the presence of a base, mainly sodium or potassium hydroxide. Despite
having good efficacy of this method, still there are some drawbacks like the need for the
protection of hydroxyl groups before the reaction, the need for analyzing the acidity of
the acetophenone hydrogen α, and obtaining biproducts if the bases are good nucleophilic
agents. As a result still different research groups are working to find some new ways to
synthesize these products to overcome the previous drawbacks111.
1.7 Chemical synthesis of α-mangostin analogs:
Different synthetic approaches available to make analogs of α-mangostin are driven by
three main perspectives aiming to overcome its structural drawbacks which are high
19

hydrophobicity, low selectivity, and low bioavailability. These three approaches target
three different parts of its structure (Figure 9): reactions involving modifications of
hydroxy groups (C1, C3 and C6 positions), reactions of aromatic electrophilic
substitution (C4 and C5 positions) and modification of prenyl moieties (C2 and C8
positions)112.
1.7.1 Modifications of hydroxy groups:
This is the most popular way to make α-mangostin analogs. The reactivity of hydroxyl
group at C1 position is less than C3 and C6 due to the possible intermolecular hydrogen
bond between the OH group at C1 and the carbonyl group at C8. So, by making milder
reaction conditions or harsher ones it is possible to control the happening of the reaction
at C3 and C6 positions only, or at all C1, C3 and C6 positions. As it is shown on Scheme
1, compounds 18 and 19 are made by reacting the α-mangostin with carbamoyl chlorides.
The compound 20 with C3-monoamide is synthesized through the intermediate
compound C6-allyl ether which is removed after the reaction with Et 2 NCOCl. Also
compounds 21 and 22 Show some analogs with ethers at C3 and C6 containing amino
groups and heterocyclic fragments. Also, compounds 26 and 27 are examples of tri-ether
which are achieved by reacting the α-mangostin with an excess of 1,4-di-iodobutane113.
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Scheme 1. Modifications of hydroxy groups of α-mangostin.
[Scheme adapted from: Buravlev, E. V., Synthesis of new derivatives of α-mangostin
(micro review). Chemistry of Heterocyclic Compounds 2019.]
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1.7.2. Reactions of aromatic electrophilic substitution:
One of the common reactions in this group is SE Ar reactions which substitute a halogen
atom at C4 position by using N-Bromosuccinimide or NBS and NCS99 or NChlorosuccinimide (Not shown in scheme 2). More recent studies suggested a Mannich
reaction in which aminomethyl groups, including heterocyclic fragments, are introduced
at C4 and then at C5 positions113-114(Scheme 2).
R2R1N
HCHO, R1R2NH(1.1 equiv)
PhH, , 30-75 min, 24-94%

HO

or
CH2(NMe2)2 (1.1 equiv)
PhH, rt, 45min, 73%

O

4

O

OH

OH

O

28
7 examples

-mangostin

R6R5N

HCHO, R3R4NH (2.5 equiv),
PhH,, 4h, 80-82%,
or CH2(NMe2)2 (2.2 equiv)
PhH, rt, 2h, then , 45min, 81%

HO

or HCHO, morpholine (1.1 equiv)
PhH, , 1.5h, then HCHO, azepane (1.5 equiv),
PhH, , 45min, 79%

R4R3N
5

O

4

O

OH

OH

O
29
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NR1R2 = pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, (thio)morpholin-4-yl, NMe2, NHBu
NR3R4 =NR5R6 = morpholin-4-yl, azepan-1-yl, NMe2
NR3R4 = morpholin-4-yl, NR5R6 = azepan-1-yl
NR3R4 =NHBu, NR5R6 = NMe2

Scheme 2. Reactions of aromatic electrophilic substitution on α-mangostin.
[Scheme adapted from: Buravlev, E. V., Synthesis of new derivatives of α-mangostin
(micro review). Chemistry of Heterocyclic Compounds 2019.]
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1.7.3 Modification of prenyl moieties:
A common reaction in this group is hydrogenation of the double bonds of the prenyl
groups at C2 and C8 positions by using Pd/C as a catalyst and other conditions slightly
different in different studies, yielding a molecule with isopentyl substituents (30)99, 108, 112.
Compounds (31-36) are afforded through oxidation reactions; depending on the oxidizing
agent, different cyclic compounds are made (Scheme 3) 112-113, 115.
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Scheme 3. Modification of prenyl moieties on α-mangostin.
[Scheme adapted from Buravlev, E. V., Synthesis of new derivatives of α-mangostin
(micro review). Chemistry of Heterocyclic Compounds 2019.]
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CHAPTER 2. HYPOTHESIS AND DESIGN RATIONALE
Chemical synthesis of α-mangostin analogs that contain a poly-oxygenated xanthone core
is not trivial due to the complexity of structure. Hence, we hypothesized that structurally
simpler, non-xanthone compounds that contain part of the α-mangostin scaffold is a
useful approach to study the SAR (structure-activity relationship) of α-mangostin. Such
an approach provides a simple and economical entry to this pharmacologically important
class of natural products. Additionally, such structurally flexible analogs of α-mangostin
have not been synthesized to date to explore their pharmacological potential.
α-Mangostin (Figure 9), similar to other xanthones, has a tricyclic planar structure and is
considered a very hydrophobic compound. Its high hydrophobicity is linked to low
solubility in aqueous medium and low selectivity in terms of adverse effects. As it has
been discussed earlier α-mangostin has a broad range of biological activities and possibly
many different targets.
Chalcones (Figure 15) as structural mimics of xanthones, although still preserve planar
structure as xanthone, demonstrated that a tricyclic core is not necessary for
pharmacological activity.
Based on this observation, we planned to develop simple chemical methods to generate
non-xanthone analogs of α-mangostin, where the oxygenated benzoyl motif is preserved,
and new functional motifs are introduced at the 2-position of the benzoyl motif (Figure
16).
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Figure 16. Key structural motifs.
Figure 16, highlights the structural motifs we proposed to include in our design of new
analogs based on the pharmacophore of α-mangostin and chalcones. By keeping the two
aryl rings and multiple hydroxyl groups that are important for the inherent
pharmacological activity of mangostins, we hope that the new analogs will retain a
reasonable bioactivity.
Moreover, having ‘non-xanthone’ core provides more flexibility, instead of rigidity,
which is known to improve a compound’s physiochemical properties and likely the
ability to bind to a desirable target. In addition, incorporation of substituted aryl rings to
the ’benzoyl core’ enables us to build a structurally diverse library of analogs and
evaluate the SAR for the non-xanthone derivative of mangostins.
To investigate this hypothesis, we proposed two different approaches.
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First, we envisioned using a commercially available polyphenol (2,4,6-trihydroxybenzoic
acid) (42) as starting material and performing structure diversification to generate a
library of synthetic analogs of α-mangostin (Scheme 4).

Scheme 4. Synthetic plan for α-mangostin analogs using 2,4,6-trihydroxybenzoate as
precursor.

A second approach was designed to synthesize α-mangostin analogs using a
commercially available methyl-4-methoxysalicylate (44) as a precursor. The plan is to
develop a simple chemical approach to alkylate compound 44 to generate a series of
analogs and explore the antibacterial activity potential.

Scheme 5. Synthetic plan for α-mangostin analogs using 4-methoxysalicylate as
precursor.
We wanted to explore the effect of structural flexibility on the bioactivity profile and
physiochemical properties of α-mangostin. Additionally, the phenyl ring of the benzyl
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ether motif (R group in compound 45) allows us to include different functional groups
such as polar and non-polar motifs that may further improve the bioactivity profile.
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CHAPTER 3. EXPERIMENTAL
3.1 Chemistry
3.1.1 Materials and Instrumentation:
All chemicals were procured from VWR International (Radnor, PA), Fisher Scientific
(Hampton, NH), AK Scientific, Inc. (CA), Acros Organics (Geel, Belgium), Aldrich
Chemical Co. (Milwaukee, WI), Alfa Aesar (Ward Hill, MA), Arkpharm, Inc. (Arlington
Heights, IL), Chem-Impex Int. Inc. (Wood Dale, IL), and were used without additional
purification. Qualitative analysis of reactions was performed by thin layer
chromatography (TLC) with silica gel G as the adsorbent (250 microns) on aluminum
backed plates (Agela Technologies) and Ultraviolet (UV) light at 254 nm or 365 nm for
visualization purposes. 1H NMR experiments were performed using a Bruker 400
UltrashieldTM spectrometer (at 400 MHz) equipped with a z-axis gradient probe. 1H
NMR chemical shifts were reported in parts per million (δ / ppm) for majority of the
intermediates and all the target compounds. The 1H NMR data are depicted as: chemical
shift multiplicity s (singlet), bs (broad singlet), d (doublet), t (triplet), dd (doublet of
doublets), dt (doublet of triplets), tt (triplet of triplets), m (multiplet), H (number of
protons) and J (coupling constant). Column chromatography purifications were
performed using silica gel (40-63 μm) purchased from Silicycle Inc. (Quebec City,
CANADA). LR-LC/MS analyses were performed on single quadrupole, Agilent
Technologies 1260 infinity series LC.
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3.1.2 General procedure for the alkylation reaction:
Methyl 4-methoxysalicylate (200 mg, 1 equiv.),K 2 CO3 (3 equiv) and NaI (0.3 equiv)
were mixed in dimethylformamide (DMF, 25 mL) and allowed to stir at room
temperature. After 20 minutes of stirring, either alkyl halide derivative (1.5 equiv) or the
benzyl bromide derivative (1.5 equiv.) was added to the suspension at room temperature
and continued to stir for 14 hours. TLC analysis after 14 hours showed complete
consumption of methyl-4-methoxysalicylate. At that point, the crude reaction mixture
was diluted with water (150 mL). The aqueous layer extracted with ethyl acetate (4 x
50mL). Combined organic layers were washed with water (3 x 50 mL), 10% NaHCO3 (50
mL), water (50 mL) and dried over anhydrous Na2 SO4 , filtered and concentrated in
vacuo to provide a pale-yellow oily material. The crude product was dissolved in minimal
amount of ethyl acetate and purified using flash column chromatography (silica gel
column, 0 to 20% EtOAc in hexanes linear gradient). The appropriate fractions were
collected and concentrated in vacuo providing the desired product as a colorless oil.

3.1.3 Representative procedure for the synthesis of Alkyl halide derivatives (Scheme
8):
O

O

O
OH
+

R

X

O

NaI, K2CO3, DMF

O
(44)

O

O
(53)
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(54) R = CH3, , X = I, Yield : 78%

R (55) R = C3H5,

X = Br, Yield : 50%

3.1.4 Characterization data for compounds 54 and 55:

Methyl 2,4-dimethoxy benzoate (54): colorless oil, 78%; 𝐑 𝐟 : 0.55 (20%
EtOAc/hexanes). 𝟏𝐇 NMR: (400MHz, CD3 OD): δ 3.80 (3H, s), 3.87 (3H, s), 3.92 (3H,
s), 6.61 (1H, dd, J = 1.5, 0.5 Hz), 6.82 (1H, dd, J = 7.6, 1.5 Hz), 7.80 (1H, dd, J = 7.6, 0.5
Hz); 𝟏𝟑𝐂𝐍𝐌𝐑: (100 MHz, CD3 OD): δ 55.9, 161.3, 55.5, 52.3, 98.8, 112.1, 133.8, 166.5,
163.2, 105.9; LC-MS: (ESI, [M+H]+) calculated for [𝐶10 𝐻12 𝑂4 + 𝐻 + ] 196.07 observed
196.0.

2-[(Allyl) oxy]-4-methoxy-methylsalicylate (55): colorless oil, 50%; 𝐑 𝐟 : 0.60 (20%
EtOAc/hexanes). 𝟏𝐇 NMR: (400MHz, CD3 OD): δ 3.80 (3H, s), 3.88 (3H, s), 4.62 (2H,
d, J = 8.6 Hz), 4.95-5.08 (2H, dd, J = 16.5, 1.3 Hz), 5.04 (dd, J = 10.7, 1.3 Hz), 6.00 (1H,
ddt, J = 16.5, 10.7, 8.6 Hz), 6.59 (1H, dd, J = 1.5, 0.5 Hz), 6.83 (1H, dd, J = 7.6, 1.5 Hz),
7.80 (1H, dd, J = 7.6, 0.5 Hz);

𝟏𝟑

𝐂𝐍𝐌𝐑: (100 MHz, CD3 OD): δ 132.9, 52.3, 55.5, 118.1,

163.2, 159.6, 105.9, 101.4, 166.5; LC-MS: (ESI, [M+H]+) calculated for [𝐶12 𝐻14 𝑂4 +
𝐻 + ] 222.09 observed 222.1.
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3.1.5 Representative procedure for the synthesis of Benzyl bromide derivatives
(Scheme 9):
O

O

O

Br
OH

70%

O

R
(44)

R
O

NaI, K2CO3, DMF

+
O

O

(57) R = F
(58) R = CF3
(59) R = H
(60) R = Cl
(61) R = CH3
(62) R = OCF3

(56)

3.1.6 Characterization data for compounds 57_62:

2-[(4-Fluorobenzyl) oxy]-4-methoxy-methylsalicylate (57): pale yellow oil, 70%; 𝐑 𝐟 :
0.45 (20% EtOAc/hexanes). 𝟏𝐇 NMR: (400 MHz,CD3 OD): δ 7.81 (1H, dd, J = 7.61,
0.47 Hz), 7.56 -7.53 (2H, ddd, J = 8.4 1.14 0.55 Hz), 7.1 (2H, ddd, J = 8.4, 1.13, 0.55
Hz), 6.65 (1H, dd, J = 1.47, 0.47 Hz), 6.59-6.57 (1H, dd, J = 7.61, 1.47 Hz), 5.1 (2H, s),
3.8 (6H, s); 𝟏𝟑𝐂 𝐍𝐌𝐑: (100 MHz, CD3 OD): δ 164.6, 160.2, 133.3, 128.7, 114.8, 105.4,
100.2, 69.4, 54.6, 50.7; LC-MS: (ESI, [M+H]+) calculated for [𝐶16 𝐻15 𝐹𝑂4 + 𝐻 + ] 290.10
observed 290.1.
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2-[(4-Trifluoromethyl) benzyl oxy]-4-methoxy-methylsalicylate (58): colorless oil,
70%; 𝐑 𝐟 : 0.32 (20% EtOAc/hexanes). 𝟏𝐇 NMR: (400 MHz,CD3 OD): δ 3.83 (3H, s),
3.88 (3H, s), 5.20 (2H, s), 6.49 (1H, dd, J = 1.5, 0.5 Hz), 6.55 (1H, dd, J = 7.6, 1.5 Hz),
7.66 (4H, s), 7.90 (1H, dd, J = 7.6, 0.5 Hz). 𝟏𝟑𝐂 𝐍𝐌𝐑: (100 MHz, CD3 OD): δ 165.95,
164.17, 159.89, 140.7, 134.1, 130.1, 126.8, 125.5, 122.78, 112.86, 105.28, 100.63, 69.68,
55.52, 51.7; LC-MS: (ESI, [M+H]+) calculated for [𝐶17 𝐻15 𝐹3 𝑂4 + 𝐻 + ] 340.09 observed
340.1.

2-benzyloxy-4-methoxy-methylsalicylate (59): colorless oil, 70%; 𝐑 𝐟 : 0.67 (20%
EtOAc/hexanes). 𝟏𝐇 NMR: (400 MHz,CD3 OD): δ 3.80 (3H, s), 3.87 (3H, s), 5.16 (2H,
s), 6.50 (1H, dd, J = 1.5, 0.5 Hz), 6.52 (1H, s), 7.25-7.38 (3H, tt), 7.40 (2H, dd, J = 7.8,
1.3 Hz), 7.87 (1H, dd, J = 7.6, 0.5 Hz). 𝟏𝟑𝐂 𝐍𝐌𝐑: (100 MHz, CD3 OD): δ 166.2, 164.1,
160.2, 136.6, 133.9, 128.55, 127.7, 126.8, 112.95, 112.9, 105.1, 100.6, 77.0, 70.58, 55.4,
51.7; LC-MS: (ESI, [M+H]+) calculated for [𝐶16 𝐻16 𝑂4 + 𝐻 + ] 272.10 observed 272.1.
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2-[(4-Chlorobenzyl) oxy]-4-methoxy-methylsalicylate (60): colorless oil,70%; 𝐑 𝐟 : 0.40
(20% EtOAc/hexanes). 𝟏𝐇 NMR: (400 MHz, CD3 OD): δ 3.81(3H, s), 3.86 (3H, s), 5.10
(2H, s), 6.48 (1H, dd, J = 1.5, 0.5 Hz), 6.84 (1H, dd, J = 7.5, 1.5 Hz), 7.36 (2H, ddd, J =
8.3, 1.1, 0.5 Hz), 7.44 (2H, ddd, J = 8.3, 1.4, 0.5 Hz), 7.87 (1H, dd, J = 7.6, 0.5 Hz);
𝟏𝟑

𝐂 𝐍𝐌𝐑: (100 MHz, CD3 OD): δ166.0, 164.12, 160.0, 135.18, 134.01, 133.5, 128.73,

128.17, 112.89, 105.24, 100.68, 77.0, 76.7, 69.81, 55.5, 51.7; ; LC-MS: (ESI, [M+H]+)
calculated for [𝐶16 𝐻15 𝐶𝑙𝑂4 + 𝐻 + ] 306.07 observed 306.0.

2-[(4-Methylbenzyl) oxy]-4-methoxy-methylsalicylate (61): colorless oil, 70%; 𝐑 𝐟 :
0.58 (20% EtOAc/hexanes). 𝟏𝐇 NMR: (400 MHz,CD3 OD): δ 2.34 (3H, s), 3.80 (3H, s),
3.86 (3H, s), 5.11 (2H, s), 6.50 (2H, dd, J = 7.6, 1.5 Hz), 7.19 (2H, dd, J = 7.5, 0.5 Hz),
7.39 (2H, J = 7.5, 0.5 Hz), 7.87 (1H, dd, J = 7.6, 0.5 Hz);

𝟏𝟑

𝐂 𝐍𝐌𝐑: (100 MHz, CD3 OD):

δ 166.28, 164.0, 160.3, 137.47, 133.88, 133.63, 129.22, 126.91, 112.98, 105.13, 100.69,
77.37, 77.05, 76.7, 55.46, 51.69, 21.20; LC-MS: (ESI, [M+H]+) calculated for [𝐶17 𝐻18 𝑂4
+ 𝐻 + ] 286.12 observed 286.1.
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2-[(4-Trifluoromethoxy) benzyl oxy]-4-methoxy-methylsalicylate (62): colorless oil,
70%; 𝐑 𝐟 : 0.36 (20% EtOAc/hexanes). 𝟏𝐇 NMR: (400 MHz,CD3 OD): δ 3.83 (3H, s), 3.87
(3H, s), 5.1 (2H, s), 6.50 (1H, dd, J = 1.5, 0.5), 6.54 (1H, dd, H = 7.5, 1.5 Hz), 7.23 (2H,
dd, J = 7.9, 1.3), 7.58 (2H, dd, J = 7.9, 1.2), 7.91 (1H, dd, J = 7.6, 0.5 Hz);

𝟏𝟑

𝐂 𝐍𝐌𝐑:

(100 MHz, CD3 OD): δ 165.97, 164.16, 160.02, 148.73, 135.39, 134.04, 128.20, 121.09,
112.89, 105.28, 100.70, 77.34, 77.02, 76.7, 55.51, 51.71; LC-MS: (ESI, [M+H]+)
calculated for [𝐶17 𝐻15 𝐹3 𝑂5 + 𝐻 + ] 356.09 observed 356.1.
3.2 Antibacterial activity evaluation:
Bacterial strain of choice was first inoculated in 10 mL of LB broth for 16 hours in
shaker at 37 ˚C. The following day, 100 µL of the inoculum was transferred to a test tube
with fresh media to obtain an inoculum with an optical density at 600 nm (OD600) of 0.2.
All compounds were dissolved in DMSO to prepare samples for testing. Drugs were
prepared as serially diluted concentration of 100, 50, 25, 12.5 and 6.25 µg/mL and 100
µL was transferred into a 96-well plate. Then 100 µL of inoculum (with OD600 = 0.2) was
transferred into each well with the test drug. The plate was then incubated at 37 °C for 14
hours. The OD600 was recorded using microplate reader (ELx808). MICs (Minimum
inhibitory concentration) are reported as the lowest concentration at which no bacterial
growth was observed.
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CHAPTER 4. RESULTS AND DISCUSSION
4.1. Synthesis of α-mangostin analogs based on 2,4,6-trihydroxybenzoic acid:
Our synthetic approach began with the conversion of 2,4,6- trihydroxybenzoic acid (42)
to the corresponding acetonide (46) to protect the carboxylic acid and the adjacent
hydroxyl. The plan is to selectively protect the hydroxyls at 4- and 6-positions with a
removable protecting group. To achieve this, first the carboxylic acid and the hydroxyl at
2-position are tied together in one step via an acetonide ring formation. It is well known
that an acetonide that connects a carboxyl group and a phenol can be converted into the
methyl ester readily. Based on literature protocol, we examined two different reaction
conditions to install the acetonide protecting group. One of the methods involved the use
of acetone and catalytic amount of 4-dimethylaminopyridine (DMAP) and resulted in a
slow, low yielding reaction116. Therefore, we shifted to the second approach where
trifluoroacetic anhydride (TFAA), trifluoroacetic acid (TFA) and acetone 117. The
acetonide (46) was obtained with an unsatisfactory yield of 39%. Based on TLC analysis,
we observed that the reaction did not go to completion and unreacted starting material
remained in the reaction mixture. Then, we increased the equivalences of TFA and TFAA
from 7.77 and 2.85 to 22 and 8.6, respectively. In addition, the reaction was performed at
30 ˚C to assess the effect of temperature. The optimized condition provided an improved
yield to 57% (Scheme 6).
With the available material, we moved forward to protect the two OH groups in
compound 46, as either benzyl ether or allyl ether118. Benzylation reaction did not
provide the desired product in good yield. We faced difficulties separating the benzyl
alcohol byproduct from the desired product. The benzyl alcohol was generated when the
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benzyl bromide reacted with residual water as the reaction mixture was not completely
anhydrous. On the other hand, allylation was successful and yielded the product in good
yield (Scheme 6). The suggested mechanism for this reaction involves deprotonation of
(OH) groups by the base (Cs2 CO3 ) and allylation of the phenoxide motif in the presence
of allyl bromide.
Following the allylation, deprotection or methanolysis of compound 47 gave compound
48 (Scheme 6). The reaction proceeded well in the presence of methanol and potassium
carbonate, where in situ generated methoxide assisted in the ring opening of acetonide,
and subsequent conversion of acetonide into the methyl ester derivative 48. Compound
48 serves as a common precursor for further derivatization at the phenolic oxygen via
alkylation. The reason for installing the allyl ethers is that after the structure
diversification of phenolic hydroxyl at 2-position, the allyl ethers can be selectively
deprotected.
To make the proposed analogs from compound 48, two different approaches were
examined. In one approach compound 48 was reacted with 1-fluoro-2,4-dinitrobenzene,
in the presence of triethylamine (TEA) at room temperature. The goal is to synthesize a
selection of ‘biaryl-ethers’ via this approach. The deprotonated phenoxide group reacted
with the fluoro-dintrobenzene via a nucleophilic aromatic substitution reaction. During
the reaction, a typical Meisenheimer complex is formed, and the fluorine is lost to
generate the desired ‘biaryl-ether’ product.
In the second approach, compound 48 was reacted with 4-(trifluoromethyl)benzyl
bromide in the presence of Cs2 CO3 at room temperature. Both of these approaches gave
the desired products with low yield (< 50%), and we had difficult time isolating the final
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products in high purity (Scheme 6). The reaction yielded a complex mixture of products
that were difficult to separate and characterize. We suspect that under the reaction
condition, the allyl groups may be migrating within compound 48, providing a mixture of
compounds. Also, the fluoro-dintrobenzene reagent may be rapidly decomposing to form
the corresponding phenol-byproduct. Our attempts to change solvents and reaction
temperature also failed to improve the yield and purity of the product. Since we had
another key step involved in the synthetic scheme, we were not satisfied with the
outcome of these two approaches. We also noticed that the yield we obtained for this
approach is not reproducible. We abandoned our strategy that involved 2,4,6trihydroxybenzoic acid as the precursor for the analog synthesis, and decided to move to
a simpler polyphenol precursor to generate the proposed analogs.
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Scheme 6. Synthesis of α-mangostin analogs via 2,4,6-Trihydroxybenzoic acid route.
The reason to abandon our initial approach also relates to the need for excessive amount
of TFA and TFAA. These reagents are corrosive, and not easy to handle in large
quantities for large scale synthesis to obtain a reasonable amount of substrate for
structure diversification.
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Therefore, we shifted our focus to an alternate approach to make simplified analogs of αmangostin using commercially available methyl-4-methoxysalicylate as a precursor (44).
While compound 44 has structural similarities with α-mangostin, it is structurally
simpler, and no protecting group manipulation is needed to generate the proposed
analogs. In this method, we envisioned derivatizing compound 44 using (1) 1-fluoro-2,4dinitrobenzenes, (2) alkyl bromides, and (3) benzyl bromides.
As shown in scheme 7a, we attempted the reaction between 1-fluoro-2,4-dinitrobenzene
(51) and the phenol precursor (44) to generate a biaryl-ether analog. It was expected that
this reaction works through a nucleophilic aromatic substitution reaction (Scheme 7b)
and results in the formation of the desired product. However, the reaction did not proceed
as expected. Analysis of the reaction by TLC indicated the presence of unreacted phenol
precursor (44). We suspect that the phenol motif is not accessible due to steric reason and
perhaps not reactive under the condition tested. Another factor to note is that 1-fluoro2,4-dinitrobenzene is not stable under the reaction condition and decomposed to the
corresponding phenol-derivative as the reaction condition is not 100% anhydrous. Due to
time constrains we had for this project, we did not further explore other methods to
generate biaryl-ethers or optimize the reaction condition. We believe that the reaction
condition may be optimized by using fresh reagents and maintaining an anhydrous
reaction environment for this type of chemistry. Moreover, elevated temperatures may be
investigated to force the reaction to go to completion.
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Scheme 7. (a) Reaction of methyl-4-methoxysalicylate and 1,4-fluoro nitro benzene
derivatives (b) Proposed mechanism.
As another direction, we also tried to alkylate the common precursor (44) with different
alkyl halides through a nucleophilic substitution reaction (SN2 ). The methylation
reaction, using methyl iodide worked well to generate the corresponding methyl ether
product. Also, the reaction using allyl bromide yielded the product in acceptable yield.
However, the other alkyl bromides, such as propyl bromide and butyl bromide did not
provide the desired products, perhaps due to low reactivity of alkyl bromides under the
tested conditions. Due to limited scope for this reaction, we did not pursue our interest in
alkyl halides for the generation of this class of methyl-4-methoxysalicylate analogs
(Scheme 8).

40

O

O

O
OH
+

(a)

R

O

NaI, K2CO3, DMF

X

O

X = Br, Yield: 50%

(53)

O

O
O

(b)

(54) R = CH3, X = I, Yield: 78%

R (55) R = C3H5,

O

(44)

O

O

H

+

-2

O
O:

CO3

R

I

+

NaX

Product

O

O
(44)

+

Base

Scheme 8. (a) Reaction between methyl-4-methoxysalicylate and alkyl halides (b)
Proposed mechanism.
Then, as shown in Scheme 9, we tried the reactivity of phenol precursor (44) with benzyl
bromide derivatives (56). This approach worked well as one-step process going through
SN2 mechanism, with good yield at room temperature. The conversion of the precursor to
the desired products (57-62) occurred in less than 4 hours, with 70-85% yield. Since
benzyl bromides are more reactive compared to alkyl bromides, the benzylation occurred
smoothly. Using this strategy, we proceeded to synthesize a series of benzyl-ethers using
five different benzyl bromides. The benzyl groups contain different substitutions at the 4postion of aryl ring (F, CF3, Cl, CH3 and OCF3). The substituents are polar or non-polar
groups and allow us to study a preliminary structure activity relationship at 4-position.
Moreover, such substitutions are useful for altering the physicochemical property of a
molecule. Moreover, by including electron donating or electron withdrawing groups,
hydrogen bond donors or acceptors, the analogs may exhibit different biological
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properties. All these compounds were purified using silica column chromatography and
fully characterized using NMR and LCMS techniques to confirm the structure.
O
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Scheme 9. (a) Reaction between methyl-4-methoxysalicylate and benzyl bromide
derivatives (b) Proposed mechanism.
Following the successful synthesis of benzyl-ether analogs of methyl-4methoxysalicylate, we went ahead and performed a preliminary antibacterial evaluation
of two of the analogs against both Gram-positive and Gram-negative bacteria.
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4.2 Characterization for compounds 47 and 61:
4.2.1 Nuclear Magnetic Resonance (NMR):
4.2.1.1 H-NMR for compound 47:
(a)

(b)

Figure 17. (a) Actual H-NMR for compound 47; (b) Predicted H-NMR for compound 47.
Since NMR plays an important role in structure determination, we selected two
compounds we have synthesized to illustrate the process involved in characterization of
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chemical structure. For compound 47, the expected number of H-NMR signals regardless
of multiplicity, can be divided into five different groups (Figure 17). Compound 47 does
not have an element of symmetry; hence, we expect all protons to have distinct chemical
shift values.
Group 1: A singlet at 1.7 ppm is observed, representing 6 protons, which represent the
two methyl groups connected to the same carbon on the acetonide ring. As these two
methyl groups are not distinguishable at the NMR timescale, they appear one singlet peak
on proton NMR spectrum. The chemical shift at 1.7 ppm matches the expected value for
an aliphatic methyl proton.

(a)

(b)

Figure 18. (a) Allyl ether different protons; (b) Allyl ether coupling constants.
Group 2: There are 2 allyl ethers in this molecule and with four distinct types of protons
(Figure 18a). Each pair of protons in two allyl ether groups are different from each other.
The allyl protons in each allyl ether group cannot be identical and each of which is
coupled with the interior vinyl proton resulting in a doublet. The presented peaks in the
actual NMR spectrum at 4.5 and 4.6 ppm match with 4 allyl protons in the two allyl ether
groups. It is possible the more downfield peak at 4.6 ppm be related to the more
deshielded allyl ether group closer to the electronegative oxygen atom.
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Group 3: These are two terminal vinyl protons of allyl ether group directly connected to
the sp2 carbon. Due to the lack of rotation around the П-bond these two protons in each
allyl ether group couple with each other. As they are magnetically different, they have
different chemical shift values. Also, each of these terminal vinyl protons couple with the
interior vinyl proton with a different coupling constant (Figure 18b). So, as each one is
coupled with 2 other protons what we can predict about the multiplicity is a doublet of
doublet. In the actual NMR spectrum, the group 3 peaks at 5.6 to 5.2 ppm can be
attributed to these terminal vinyl protons. The coupling constant between the two
germinal protons is around 2 Hz and the coupling constant between the interior vinyl
proton and the trans alkene proton is around 15 Hz. The cis alkene proton has a coupling
constant value of 10 Hz. Based on the coupling constant values, it is possible that two of
the middle peaks would have been very close to each other which are not possible to be
distinguished from each other and that is the reason in the presented NMR spectrum, 6
peaks are seen instead of 8 peaks within the expected region.
Group 4: This group can perfectly be attributed to the interior vinyl hydrogen in allyl
ether group which has a particularly interesting resonance. This hydrogen couples to
other four hydrogens in the allyl ether group with three different coupling constants
(Figure 18b) and makes a very distinct multiplicity. As these interior vinyl hydrogens in
each of the two allyl ether groups are in the same environment their chemical shifts are at
around 5.6 ppm.
Group 5: This group represents the aromatic protons on benzene ring. On the NMR
spectrum, the aromatic peaks are at around 6.2 ppm, which are in the lower ppm region
of the spectrum within the aromatic region. Since the aryl ring has electron donating
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groups, the electronic of the ring gives these aryl protons a chemical shift around 6 ppm.
In other words, the lone pair of electrons of oxygens on the aryl ring push the electron
density into the ring via resonance, making the aryl proton peaks appear more upfield.
Also, as there is no symmetry in this molecule and each of the two aromatic hydrogens
are in different chemical environments, the two protons have distinct chemical shifts.
Moreover, lack of neighboring protons to couple, the peaks appear as singlet.
4.2.1.2 H-NMR for compound 61:
(a)
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(b)

Figure 19. (a) Actual H-NMR for compound 61; (b) Predicted H-NMR for compound 61.
Group 1: The methyl group on the 4-position of the benzyl unit is similar to the methyl
group on toluene, which based on data in the Spectral Database for Organic Compounds
maintained by the Japanese AIST, has the chemical shift of 2.34 ppm in CDCl3 . The
chemical shift for this peak in our actual NMR spectrum (Figure 19a) is exactly at 2.34
ppm, confirming its assignment.
Group 2: This methyl group is part of the ester functional group where the methyl group
is connected to oxygen atom. It makes this methyl group more deshielded than an
aliphatic methyl group, and that is why the peak appears more downfield at 3.8 ppm in
the NMR spectrum. As the three hydrogens on the methyl group are chemically and
magnetically equivalent, it appears as a singlet.
Group3: This methyl group is directly connected to the oxygen atom on an aryl ring.
Hence, it is deshielded and shows up more downfield at 3.86 ppm. Like other methyl
groups, it also shows up as a singlet on the NMR spectrum.
Group 4: This peak represents the benzylic protons. Since the -CH2- group is connected
to an aryl ring and an oxygen atom, the signal for these protons is shifted downfield to
5.1 ppm.
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Group 5: The proton in this group is on the benzene ring and expected to be seen at
around 6.5 – 8.0 ppm range. As there are two electron donating groups next to this
hydrogen (-OR), the protons on the ring are more shielded and show up more upfield.
The signal for these protons is observed near 6.5 ppm. Figure 19a shows two peaks next
to each other at 6.5 ppm, as a singlet and a doublet. The singlet peak at this chemical shift
represents the proton in this group with no neighboring proton to couple.
Group 6: This is another hydrogen on the aromatic ring next to an electron donating
group (-OR) and another hydrogen. As there is an electron donating group next to it, it is
not surprising to see the peak more upfield and near 6.5 ppm. Also, as it is shown in
Figure 18a There are two peaks at 6.5 ppm next to each other, a singlet and a doublet,
which the doublet one is attributed to this hydrogen. This proton couple with the adjacent
hydrogen on the aryl ring and appears as a doublet.
Group 7: In the proton NMR (Figure 19a), there is a symmetrical doublet-doublet pattern
at 7.2 ppm and 7.4 ppm which is extremely a strong evidence for para-substituted
benzene. These two doublets represent the four protons on the aryl ring of the benzyl
group. Each two protons opposite each other on the benzene ring can be assumed to be in
the same chemical and magnetic environment. So, each set is represented in one peak and
appears as doublet due to coupling with adjacent aryl proton.
Group 8: This is the most downfield peak at 7.8 ppm which stands for the hydrogen on
the benzene ring next to a carbonyl group. As the carbonyl group is an electron
withdrawing group, it is expected the adjacent hydrogen would be less shielded and
shows up more downfield. Figure 18a shows the chemical shift and the splitting pattern
for this peak.
48

4.3 Antibacterial evaluation of selected methyl-4-methoxysalicylate analogs:
Since α-mangostin is known to exhibit antibacterial activity against a broad range of
bacteria, we investigated the antibacterial activity of the synthetic analogs we have
generated. As a first step, we selected two benzyl-ether analogs (58 and 60) for the
antibacterial evaluation. The studies were done using standard Gram-positive strains (two
different S. aureus, and a S. epidermidis) that show greater sensitivity to antibiotics and
α-mangostin. Since these Gram-positive bacteria are relatively easy to cultivate in the
laboratory, and commonly used for antibiotic discovery efforts, we selected these bacteria
for our evaluation. Additionally, these bacteria are also associated with various types of
infections in clinical setting. The data are shown in Table 1 below. The minimum
inhibitory concentration (MIC) value determination was done by a Ph.D. student, Nikita
Acharekar in the Yoganathan lab. Ciprofloxacin and α-mangostin were used as positive
control and exhibited potent MIC values in the range of 0.01 – 0.6 µg/mL. We found that
the synthetic analogs 58 and 60 showed no antibacterial activity even at 100 µg/mL.
Although the biological data is not promising at this stage, our plan is to continue to test
the remaining analogs against a panel of bacteria. In addition, as anti-cancer property of
this group of compounds is an interest to us, we may be exploring the anti-cancer activity
of these analogs in the future.
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MIC values (µg/mL)

S. aureus
(ATCC
12600)
0.6

S. epidermidis
(ATCC 12228)

α-mangostin

S. aureus
(ATCC
29213)
0.01

ciprofloxacin

0.3

0.3

0.3

58

>100

>100

>100

>100

>100

>100

Compound
name or #

60

Compound
Structure

O

O

Cl
O

O

Table 1. Antibacterial activity of selected methyl-4-methoxysalicylate analogs.
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0.6

CHAPTER 5. CONCLUSION
Herein, we report a direct and efficient approach to access several non-xanthone αmangostin analogs. Currently reported methods in the literature are using commercially
available α-mangostin to make new analogs with improved efficacy and less toxicity99,
103, 105, 108, 119

. But our approach utilizes a simple commercially available phenolic acid

substrate to prepare a series of ‘non-xanthone’ derivatives for medicinal chemistry
evaluation. We have developed a synthetic method to make α-mangostin analogs by
using the commercially available methyl-4-methoxysalicylate as the precursor, and
selectively modified the phenol motif in a one-step process. Our approach generated a
series of benzyl ether analogs via one-step synthesis. Since there is a large array of benzyl
halides available commercially, one can use our method to generate an extensive library
of analogs for medicinal chemistry studies. Although our initial antibacterial study did
not provide any potent analogs, we believe that using the chemistry we developed, more
analogs can be synthesized to identify potential antibacterial compounds of this nature.
Additionally, these analogs we have generated can be tested against other pathogenic
bacteria and likely for cytotoxicity against cancer cell lines.
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